The US FDA has approved tavapadon (Juvmo) for the treatment of Parkinson’s disease in adults. Tavapadon is a non-ergot dopamine agonist and the first selective partial dopamine D1 and D5 receptor agonist approved for Parkinson’s disease. Clinical evidence The efficacy of tavapadon was evaluated in three randomized, placebo-controlled clinical trials, as monotherapy in patients not receiving concomitant levodopa and as adjunctive therapy to levodopa.

In Studies 1 and 2, efficacy was assessed by the change from baseline in the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II score at Week 26. In Study 3, the primary endpoint was change in total daily ON time without troublesome dyskinesia. Study 1 : Among 529 patients (mean age, 63.7 years) who received tavapadon 5 mg, 15 mg, or placebo once daily without concomitant…